PeopleBio R&D

Seongnam-si, South Korea Founded: 2002 • Age: 24 yrs
Immunoassays are developed for early detection of neurodegenerative diseases.
Annual revenue $2.5M Latest available
Total funding - Funding intelligence
Employees 60 Tracked headcount
Investors - Known backers
Products - Services tracked
Competitors 8 Brand Intelligence

About PeopleBio R&D

PeopleBio R&D is a company based in Seongnam-si (South Korea) founded in 2002. The company has 60 employees as of December 31, 2024. PeopleBio R&D operates in a competitive market with competitors including Cytox, ADx NeuroSciences, Amprion, Durin Technologies and Adlyfe, among others.

  • Headquarter Seongnam-si, South Korea
  • Employees 60 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Legal Name Peoplebio. Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $2.53 M (USD)
    -16.2
    as on Dec 31, 2024
  • Net Profit
    -$7.4 M (USD)
    31.94
    as on Dec 31, 2024
  • EBITDA
    -$6.77 M (USD)
    27.03
    as on Dec 31, 2024
  • Latest Funding Round
    Not available
  • Investors
    Not available
  • Employee Count
    60

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of PeopleBio R&D

PeopleBio R&D is a publicly listed company on the KRX with ticker symbol 304840 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: KRX · Ticker: 304840 · Sector: Health technology · South Korea

Funding Insights of PeopleBio R&D

Premium access

Detailed funding history for PeopleBio RD

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by PeopleBio R&D

Investments
Premium access

Investment portfolio details for PeopleBio RD

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - PeopleBio RD

Premium access

Detailed financials for PeopleBio RD

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Peoplebio R&D Comparisons

PeopleBio R&D Primary company
Description
Immunoassays are developed for early detection of neurodegen...
Location
Seongnam-si, South Korea
Founded Year
2002
Annual Revenue
$2.53 M (USD)
Net Profit
-$7.4 M (USD)
EBITDA
-$6.77 M (USD)
Employees
60
As of 2024
Premium access

Peer comparison for PeopleBio RD

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of PeopleBio R&D

PeopleBio R&D operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cytox, ADx NeuroSciences, Amprion, Durin Technologies and Adlyfe, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Prognostic tests for assessing dementia risk are developed.
Locked Locked Locked
Biomarker assays for neurodegenerative diseases are developed using custom antibodies.
Locked Locked Locked
Assay technology for misfolded proteins in neurodegenerative disorders is developed.
Locked Locked Locked
Developer of the diagnostic test for neurodegenerative diseases
Locked Locked Locked
Develops biomarkers and diagnostic tests for amyloid-related diseases.
Premium access

Detailed competitors of PeopleBio RD

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Peoplebio R&D

Premium access

Complete news archive for PeopleBio RD

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about PeopleBio R&D

PeopleBio R&D was founded in 2002.

PeopleBio R&D is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.

As of Dec 31, 2024, the latest employee count at PeopleBio R&D is 60.

Annual revenue of PeopleBio R&D is $2.53M as on Dec 31, 2024.

PeopleBio RD was founded in 2002 in Seongnam-si, South Korea, as a molecular diagnostics firm. Focus is placed on immunoassays for detecting neurodegenerative conditions like Alzheimers and Parkinsons. The Multimer Detection System platform is utilized, involving sandwich ELISA tests with capturing and detection antibodies to identify protein multimers in CSF, plasma, exosomes, and body fluids. Tests are also created for therapeutic antibodies and spongiform encephalopathies.

PeopleBio R&D's top competitors include Amprion, ADx NeuroSciences and Cytox.

Yes, PeopleBio R&D is publicly traded on KRX under the ticker symbol 304840.

The ticker symbol of PeopleBio R&D is 304840 on KRX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available